Search the Newsreel

Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Summit Therapeutics has disclosed a "going concern" risk due to insufficient cash and short-term investments to fund its operations for the next year. The company, despite raising $299.2 million through its ATM facility, expects continued operating losses and is exploring financing options. Summit Therapeutics …

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Summit Therapeutics announced its financial results for Q2 and H1 2026, highlighting significant progress in the clinical development of ivonescimab, a bispecific antibody for cancer treatment. The company reported consistent overall survival data for ivonescimab in NSCLC patients across Western and Asian populations, with …

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ...

Summit Therapeutics Inc (SMMT) reported a strong cash position of $690.7 million in Q2 2026 and positive clinical data for its lead asset, Ivanizumab, with collaborations and a broad trial pipeline. However, operating expenses increased, and Ivanizumab still needs statistically significant overall survival benefits …

Summit Therapeutics (SMMT) sets up $380M at-the-market share offering

Summit Therapeutics (SMMT) has established an at-the-market (ATM) equity program to offer and sell up to $380 million of common stock through J.P. Morgan Securities LLC. The proceeds are primarily intended to fund the development of its lead oncology candidate, ivonescimab, for various cancer …

Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026

Earnings Call Insights: Summit Therapeutics (SMMT) Q2 2026 MANAGEMENT VIEW * Robert Duggan (Co-CEO & Executive Chairman) said, "we expand our clinical development plan and prepare for commercialization in anticipation of a decision from the FDA on our BLA towards the end of this …

Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Summit Therapeutics (SMMT) drew fresh attention after releasing updated overall survival data from its global Phase III HARMONi trial of ivonescimab plus chemotherapy, …

Summit Therapeutics (NASDAQ: SMMT) posts loss, eyes FDA decision

Summit Therapeutics reported a net loss of $215,700 for the quarter and $405,124 for the six months ended June 30, 2026, and acknowledged that its current liquidity is insufficient to fund operations for at least one year, raising substantial doubt about its ability to …

SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides details on Summit Therapeutics Inc. (SMMT), including its latest stock price ($13.58, up 9.35%), market capitalization ($11.63B), and recent news. Key updates include strong lung cancer survival results reported by Summit and its financial results for Q2 2026. The article also …

Summit Therapeutics says cash crunch could impact its ability to continue

Summit Therapeutics (SMMT) announced that its current cash reserves are insufficient to fund operations for at least the next year, leading to a ~5% drop in shares during after-hours trading. The company's cash crunch raises concerns about its ability to continue operations.

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit Therapeutics SMMT announced updated overall survival ("OS") data from the phase III HARMONi study evaluating its investigational antibody ivonescimab in certain patients with non-small cell lung cancer ("NSCLC"). The company reported more favorable OS data in the latest June 2026 analysis, driven by …

H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics

H.C. Wainwright has reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ:SMMT) with no 12-month price target. The firm noted Summit's disclosure of a third HARMONi OS analysis, which reduces concerns about the global survival benefit of ivonescimab and supports its pending BLA. Despite …

Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Summit Therapeutics stock has delivered a very large 3 year gain, but its recent slide and a low overall value score suggest the …

Did New HARMONi Survival Data Just Shift Summit Therapeutics' (SMMT) Ivonescimab Investment Narrative?

Summit Therapeutics recently reported updated overall survival results from its global Phase III HARMONi trial, showing that ivonescimab plus platinum-doublet chemotherapy continued to deliver a positive survival trend and consistent safety profile versus chemotherapy alone in both Asian and western patients with advanced EGFR-mutated …

Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17

Summit Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-07-23

Summit Therapeutics reported its Q2 2026 earnings, highlighting the significant progress of its drug Ivonescimab, a PD-1/VEGF bispecific antibody, which has shown strong efficacy in Phase III trials and is awaiting FDA approval. The company announced $690.7 million in cash and short-term investments but …

Summit Therapeutics (NASDAQ:SMMT) Releases Earnings Results, Beats Estimates By $0.08 EPS

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Data Expected to Be Generated by Mid-2027 HAYWARD, Calif. & MIAMI, July 22, 2026--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, and Summit Therapeutics …

SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings

Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug

Summit Therapeutics announced that extended follow-up data from its HARMONi study for the lead cancer drug, ivonescimab, shows stronger survival advantages in patients with EGFR-mutated non-small cell lung cancer. The latest analysis demonstrated an improved hazard ratio for overall survival, aligning with results from …

Summit: Updated HARMONi OS Analysis Shows HR 0.76 for Ivonescimab Across Global Population

Summit Therapeutics reported updated HARMONi overall survival results for ivonescimab, showing a hazard ratio of 0.76 in both the full population and the western subgroup. The updated analysis, with a data cutoff of June 2026, also noted an acceptable safety profile, with detailed data …

Summit Therapeutics stock rises on positive cancer trial data

Summit Therapeutics' stock rose 3% following positive updated overall survival results from its Phase III HARMONi clinical trial for ivonescimab in

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

Western Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study MIAMI, July 22, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial …

Summit Therapeutics (SMMT) Is Down 5.4% After Out-Licensing Ridinilazole To Biossil Inc.

Summit Therapeutics (SMMT) has out-licensed its Phase III antibiotic, ridinilazole, to Biossil Inc. for an upfront payment of US$500,000 and potential milestones up to US$104.5 million. This move is strategic, allowing Summit to focus on its oncology programs, particularly ivonescimab, and monetize a non-core …

Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring a Potential 108.75% Upside in Biotech

Summit Therapeutics Inc. (SMMT) is a biopharmaceutical company focusing on groundbreaking therapies for conditions like non-small lung cancer and colorectal cancer, with its flagship product ivonescimab in Phase III trials. Analysts project a potential upside of 108.75% from its current stock price, despite the …

Summit Therapeutics (SMMT) Projected to Post Earnings on Thursday

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

Summit Therapeutics (SMMT; SUMM) has divested its investigational Phase 3 antibiotic, ridinilazole, to Biossil for up to US$104.5 million in milestones, signaling a strategic shift to focus entirely on its oncology drug, ivonescimab. This move comes as the company aims to capitalize on the …

Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026

Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call on Thursday, July 23, 2026, at 4:30 p.m. EDT to discuss its second-quarter 2026 financial results and operational progress. The biopharmaceutical oncology company, focused on developing medicinal therapies, will provide access to the live …

Summit Therapeutics schedules July 23 update on operations

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal

Summit Therapeutics has sold its investigational antibiotic ridinilazole to Biossil Inc. for an upfront payment of US$500,000, with potential future milestones up to US$104.5 million and tiered royalties. While this deal provides a potential long-term income stream and shifts focus to oncology, Summit's primary …

Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Summit Therapeutics: It Still Feels Like The Market Got Ahead Of Itself (NASDAQ:SMMT)